137 related articles for article (PubMed ID: 10541319)
1. Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition.
Verheul HM; Panigrahy D; Flynn E; Pinedo HM; D'Amato RJ
Pediatr Res; 1999 Nov; 46(5):562-5. PubMed ID: 10541319
[TBL] [Abstract][Full Text] [Related]
2. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
4. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
[TBL] [Abstract][Full Text] [Related]
5. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
7. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
8. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
10. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
11. Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice.
Shibuya K; Kuwaki T; Akahori H; Kato T; Miyazaki H
Leuk Res; 2004 Sep; 28(9):941-6. PubMed ID: 15234571
[TBL] [Abstract][Full Text] [Related]
12. Effect of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on growth and differentiation of the HEL cell line.
Catani L; Gugliotta L; Motta M; Tazzari P; Baravelli S; Tura S
Haematologica; 1998 May; 83(5):385-91. PubMed ID: 9658720
[TBL] [Abstract][Full Text] [Related]
13. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
Farese AM; MacVittie TJ; Roskos L; Stead RB
Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
[TBL] [Abstract][Full Text] [Related]
15. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
16. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
Ide Y; Harada K; Imai A; Yanagida M
Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
[TBL] [Abstract][Full Text] [Related]
17. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
[TBL] [Abstract][Full Text] [Related]
18. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
Harker LA; Marzec UM; Novembre F; Sundell IB; Waller EK; Karpatkin S; McClure HM; Kelly AB; Stead RB
Blood; 1998 Jun; 91(12):4427-33. PubMed ID: 9616135
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
20. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice.
Ulich TR; del Castillo J; Senaldi G; Cheung E; Roskos L; Young J; Molineux G; Guo J; Schoemperlen J; Munyakazi L; Murphy-Filkins R; Tarpley JE; Toombs CF; Kaufman S; Yin S; Nelson AG; Nichol JL; Sheridan WP
Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
